株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の非アルコール性脂肪性肝炎バイオマーカー市場調査と予測

Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 785701
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.30円で換算しております。
世界の非アルコール性脂肪性肝炎バイオマーカー市場調査と予測 Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2018-2023
出版日: 2019年01月21日 ページ情報: 英文
概要

当レポートでは、世界の非アルコール性脂肪性肝炎バイオマーカー市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 レポートのサマリー

第2章 市場概要と洞察

  • 定義
  • アナリストの見解と現在の市場動向
  • 規則と法規制

第3章 市場決定因子

  • 促進因子
    • 非アルコール性肝臓疾患の罹患率の上昇
    • 非アルコール性脂肪性肝炎検出技術に対する資金援助
    • 感染症の罹患率上昇
    • 2型糖尿病などの生活習慣病の罹患率上昇
  • 阻害因子
    • 画像技術などの代用技術の利用可能性
    • 一人当たりの投資
  • 機会
    • 治験数の増加
    • 新興国における慢性肝臓疾患に対する意識の高まり
    • 薬剤モニタリングのための非侵襲性診断ツールの対する動き

第4章 市場セグメンテーション

  • バイオマーカータイプ別
    • 血清バイオマーカー
    • 肝臓線維バイオマーカー
    • アポトーシスバイオマーカー
    • 酸化ストレスバイオマーカー
    • その他
  • エンドユーザー別
    • 病院
    • 診断試験所
    • 学術研究機関
    • 製薬会社/CRO

第5章 競合環境

  • 戦略分析
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の諸国

第7章 企業プロファイル

  • Allergan PLC
  • ALPCO
  • Antaros Medical AB
  • BioPredictive S.A.S
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Covance Inc.
  • Enterome SA
  • GENFIT SA
  • Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • NGM Biopharmaceuticals, Inc.
  • Nordic Bioscience
  • OWL Metabolomics
  • Perspectum Diagnostics Ltd
  • Prometheus Laboratories Inc.
  • ProSciento
  • Quest Diagnostics Inc.
  • Siemens Healthcare Medical Solutions Ltd.
  • Thermo Fisher Scientific, Inc.
  • Xeptagen SpA.
図表

List of Tables

  • TABLE # 1 GLOBAL NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY BIOMARKER TYPE, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL SERUM BIOMARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL HEPATIC FIBROSIS MARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL ADOPTOSIS MARKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL OXIDATIVE STRESS MAKERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL ACADEMIC RESEARCH INSTITUTE MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL PHARMACEUTICAL COMPANIES/CRO MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 13 NORTH AMERICA NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 14 NORTH AMERICA NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 15 NORTH AMERICA NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 16 EUROPE NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 17 EUROPE NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 18 EUROPE NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 19 ASIA-PACIFIC NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 20 ASIA-PACIFIC NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 21 ASIA-PACIFIC NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)
  • TABLE # 22 ROW NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 23 ROW NASH BIOMARKERS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL NASH BIOMARKERS MARKET SHARE BY TYPE, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL NASH BIOMARKERS MARKET SHARE BY END-USERS, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL NASH BIOMARKERS MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
  • FIGURE # 4 US NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 5 CANADA NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 UK NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 GERMANY NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 ITALY NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 SPAIN NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 FRANCE NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 ROE NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 INDIA NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 CHINA NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 JAPAN NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 REST OF ASIA-PACIFIC NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 ROW NASH BIOMARKERS MARKET SIZE, 2017-2023 ($ MILLION)
目次
Product Code: OMR2019504

Non-alcoholic Steatohepatitis (NASH) is a type of NAFLD (Non-alcoholic fatty liver disease), a condition in which fat develops in the liver. NASH normally develops in patients affected with one of the conditions, including dyslipidemia, glucose intolerance, and obesity. To detect NASH disease, some invasive and non-invasive methods are available which include liver biopsy, imaging technology, and biomarkers. Biomarkers are considered one of the non-invasive techniques for the diagnosis of NASH among patients. Several non-invasive biomarkers and panels have been tested with an objective to determine liver fibrosis. For instance, Enhanced liver fibrosis (ELF) and NASH FibroSure are certain panels used to test for liver fibrosis.

Moreover, there are several factors boosting the global NASH biomarkers market, including increasing funding for NASH detection techniques. For instance, in November 2017, GENFIT SA has contributed to around $39 million in the LITMUS initiative, led by the two-joint undertaking of European Innovative Medicines Initiative (IMI) for the development of non-invasive biomarkers. This aimed to develop new and effective biomarkers for better diagnosis of patients having affected with NAFLD. In addition, it enables to identify those who are at higher risk of developing critical inflammation and liver scarring. It represents the growing focus of European government and companies towards developing more accurate diagnostic biomarkers for NASH detection. This, in turn, accelerates the demand for NASH biomarkers and enables the market to grow across the globe. Additionally, NASH programs in the US & Europe and increasing partnerships to develop NASH biomarkers are further contributing towards the market growth. However, high capital investment and availability of substitute such as imaging technology are restricting the growth of NASH biomarkers market.

The global non-alcoholic steatohepatitis biomarkers market is further analyzed on the basis of the geographical regions, which includes North America, Europe, Asia-Pacific, and Rest of the World, that are significantly contributing towards the growth of the market. Europe and North America are expected to hold a significant share in the global NASH biomarkers market due to increasing awareness programs and significant funding provided by the government organizations and pharmaceutical companies. Moreover, the presence of major players in these regions is further leveraging the market growth in these regions. Asia-Pacific is anticipated to witness the fastest growth rate in the global NASH biomarkers during the forecast period. This is majorly due to increasing awareness of chronic liver conditions in the region.

Some of the key vendors operating in the global NASH biomarkers market are Thermo Fisher Scientific, Inc., GENFIT SA, Nordic Bioscience, Siemens Healthcare GmbH, OWL Metabolomics, and Gilead Sciences, Inc., among others. Mergers & acquisitions and partnerships adopted by these players to be competitive in the market. For example, in June 2017, OWL Metabolomics and ProSciento partnered to set up a database of potential clinical study participants that are assessed for the presence of NAFLD and NASH with the use of OWL's lipidomics-based and non-invasive diagnostic assays. This is expected to improve the identification of people having NASH and NAFLD by utilizing non-invasive blood tests.

Research methodology

The market study of global non-alcoholic steatohepatitis biomarkers market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Authentic Public Databases such as National Institutes of Health (NIH), among others.
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for government and private companies for overall market analysis and competitive analysis. The report provides in-depth analysis of pricing, market size, intended quality of the product preferred by consumers and initial norms. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market segmentation

Global NASH biomarkers market is segmented on the basis of regional outlook and following segments:

  • 1. Global NASH Biomarkers Market Research and Analysis by Biomarker Type
  • 2. Global NASH Biomarkers Market Research and Analysis by End-users
  • 3. Global NASH Biomarkers Market Research and Analysis by Region

The report covers:

  • Comprehensive research methodology of the global non-alcoholic steatohepatitis biomarkers market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global non-alcoholic steatohepatitis biomarkers market.
  • Insights about market determinants which are stimulating the global non-alcoholic steatohepatitis biomarkers market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. REPORT SUMMARY

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. Definition
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendation
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

CHAPTER 3. MARKET DETERMINANT

  • 3.1. Motivators
    • 3.1.1. Increasing Prevalence of Non-Alcoholic Liver Diseases
    • 3.1.2. Increasing Funding for NASH Detection Techniques
    • 3.1.3. Rising Prevalence of Infectious Diseases
    • 3.1.4. Rising Prevalence of Lifestyle Oriented Diseases Such as Type-2 Diabetes
  • 3.2. Restraints
    • 3.2.1. Availability of Substitute Such as Imaging Technology
    • 3.2.2. High Capital Investment
  • 3.3. Opportunities
    • 3.3.1. Rising Number of Clinical Trials
    • 3.3.2. Rising Awareness for Chronic Liver Diseases in Emerging Economies
    • 3.3.3. Shift Towards Non-Invasive Diagnostic Tools for Monitoring of Drugs

CHAPTER 4. MARKET SEGMENTATION

  • 4.1. Global NASH Biomarkers Market by Biomarker Type
    • 4.1.1. Serum Biomarkers
    • 4.1.2. Hepatic Fibrosis Biomarkers
    • 4.1.3. Apoptosis Biomarkers
    • 4.1.4. Oxidative Stress Biomarkers
    • 4.1.5. Others (Carbon Isotope Markers and miRNA Biomarkers)
  • 4.2. Global NASH Biomarkers Market by End-Users
    • 4.2.1. Hospitals
    • 4.2.2. Diagnostic Laboratories
    • 4.2.3. Academic Research Institute
    • 4.2.4. Pharmaceutical Companies/CRO

CHAPTER 5. COMPETITIVE LANDSCAPE

  • 5.1. Key Company Analysis
  • 5.2. Key Strategy Analysis

CHAPTER 6. REGIONAL ANALYSIS

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Roe
  • 6.3. Asia-Pacific
    • 6.3.1. India
    • 6.3.2. China
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of The World (RoW)

CHAPTER 7. COMPANY PROFILES

  • 7.1. Allergan PLC
  • 7.2. ALPCO
  • 7.3. Antaros Medical AB
  • 7.4. BioPredictive S.A.S
  • 7.5. Boehringer Ingelheim International GmbH
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Covance Inc.
  • 7.8. Enterome SA
  • 7.9. GENFIT SA
  • 7.10. Gilead Sciences, Inc.
  • 7.11. Laboratory Corporation of America Holdings
  • 7.12. NGM Biopharmaceuticals, Inc.
  • 7.13. Nordic Bioscience
  • 7.14. OWL Metabolomics
  • 7.15. Perspectum Diagnostics Ltd
  • 7.16. Prometheus Laboratories Inc.
  • 7.17. ProSciento
  • 7.18. Quest Diagnostics Inc.
  • 7.19. Siemens Healthcare Medical Solutions Ltd.
  • 7.20. Thermo Fisher Scientific, Inc.
  • 7.21. Xeptagen SpA.